Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
     
  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.
     
  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — …

Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
     
  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.
     
  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — …

Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
  • Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics
  • Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide
  • Acquisition further demonstrates Sandoz commitment to pioneer access for patients

Basel, March 14, 2022 — Sandoz, a Novartis division, announced today that it has successfully acquired the UK-based medical and drug delivery device …

Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
  • Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4
  • Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions1,2
  • Sandoz is committed to developing and providing generic oncology therapies, to provide patients access to affordable, high-quality …
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Ad hoc announcement pursuant to Art. 53 LR

  • Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)
    • IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)
    • Sandoz sales grew +2% (cc, 0% USD) and core operating income in line with prior year (0% cc, 0% USD)
  • Full year net sales grew +4% (cc, +6% USD) driven by strong Innovative Medicines performance
    • Innovative Medicines (IM …
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Ad hoc announcement pursuant to Art. 53 LR

  • Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)
    • IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)
    • Sandoz sales grew +2% (cc, 0% USD) and core operating income in line with prior year (0% cc, 0% USD)
  • Full year net sales grew +4% (cc, +6% USD) driven by strong Innovative Medicines performance
    • Innovative Medicines (IM …
Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
  • Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.
     
  • Breast cancer is one of most common types of cancer in women, accounting for over 355,000 new cases in 2020 in Europe alone1
     
  • Sandoz has been developing and providing oncology medicines for over 30 years, to expand access to and increase affordability of high quality medicines
     

Basel, December 22, 2021 — Sandoz, a global …

Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
  • Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.  
     
  • Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers1,2
     
  • Sandoz continues to build on leading generic and biosimilar oncology portfolio to increase patient access and contribute to sustainability of healthcare systems

Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz

Ad hoc announcement pursuant to Art. 53 LR

  • Q3 net sales grew +5% (cc¹, +6% USD)
    • Innovative Medicines grew +7% (cc, +8% USD)
    • Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx (+22% cc), Kesimpta (USD 109 million), Jakavi (+26% cc), Zolgensma (+28% cc), Promacta/Revolade (+18% cc) and Kisqali (+27% cc)
    • Sandoz declined -2% (cc, -1% USD), affected by continued pricing pressures. Ex-US sales grew …
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
  • At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia
  • New agreement follows earlier supply agreement for the fill and finish of more than 50 million doses in 2021 at the Novartis Stein site in Switzerland

Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding …